QL Biopharm
Latest round
- Series C
Last raised
- Sep 2026
Total raised
- $130M
Investors
- 31
About QL Biopharm
, trading as QL Biopharm, operates as a recombinant protein drug provider, focusing on the production of recombinant protein drugs. Xujia Zhang, the founder and the CEO of the company, was a researcher at the Institute of Biophysics, Chinese Academy of Sciences. The core members of the company's research and development team used to work at Novo Nordisk, Gan & Lee and other pharmaceutical companies. QL Biopharm has established a research and development center in Beijing and a production base in Taizhou, China. It was awarded honors such as Specialized, Refined, Featured and Original SMEs in Beijing and National High-tech Enterprise. The company's technology platforms include QL Fold, QL Long, QL Fusion and QL Oral. The company has 10 recombinant protein innovators and biosimilars under development in its product pipeline, including two international class I innovators and one large biosimilar. QL Biopharm's drugs can be used to treat diabetes, obesity, non-alcoholic steatohepatitis and other diseases. The company generates revenue from providing recombinant protein drugs.
Who invested in QL Biopharm
31 investors across 9 rounds
See all investors in QL Biopharm
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Sep 14, 2026
Amount
Undisclosed
Investors
Series C
Mar 2, 2026
Amount
$73M
Investors
Series C
Jan 26, 2026
Amount
Undisclosed
Investors
Series C
Feb 17, 2025
Amount
$14M
Investors
Series B
Nov 27, 2023
Amount
$28M
Investors
Series B
Mar 5, 2023
Amount
Undisclosed
Investors
Series A
May 25, 2021
Amount
Undisclosed
Investors
Series A
Oct 27, 2020
Amount
$15M
Investors
Angel
Apr 2, 2019
Amount
Undisclosed
Investors
Questions about QL Biopharm
Who invested in QL Biopharm?
QL Biopharm has 31 investors on record across 9 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has QL Biopharm raised?
QL Biopharm has raised 9 venture rounds. Sign up free to see how much each round raised and the total.
When did QL Biopharm last raise money?
QL Biopharm's most recent round on record is a Series C, in Sep 2026.
What does QL Biopharm do?
, trading as QL Biopharm, operates as a recombinant protein drug provider, focusing on the production of recombinant protein drugs.
Where is QL Biopharm headquartered?
QL Biopharm is headquartered in Beijing, China.
Which VCs invest in companies like QL Biopharm?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at QL Biopharm's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like QL Biopharm? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.